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NIPTmer: rapid k-mer-based 
software package for detection of 
fetal aneuploidies
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Kaarel Krjutškov4,8,9, Andres Salumets2,4,5,10 & Lauris Kaplinski1
Non-invasive prenatal testing (NIPT) is a recent and rapidly evolving method for detecting genetic 
lesions, such as aneuploidies, of a fetus. However, there is a need for faster and cheaper laboratory and 
analysis methods to make NIPT more widely accessible. We have developed a novel software package 
for detection of fetal aneuploidies from next-generation low-coverage whole genome sequencing data. 
Our tool – NIPTmer – is based on counting pre-defined per-chromosome sets of unique k-mers from raw 
sequencing data, and applying linear regression model on the counts. Additionally, the filtering process 
used for k-mer list creation allows one to take into account the genetic variance in a specific sample, 
thus reducing the source of uncertainty. The processing time of one sample is less than 10 CPU-minutes 
on a high-end workstation. NIPTmer was validated on a cohort of 583 NIPT samples and it correctly 
predicted 37 non-mosaic fetal aneuploidies. NIPTmer has the potential to reduce significantly the time 
and complexity of NIPT post-sequencing analysis compared to mapping-based methods. For non-
commercial users the software package is freely available at http://bioinfo.ut.ee/NIPTMer/.
Non-invasive prenatal testing (NIPT) is an expanding clinical application in which circulating cell-free DNA 
(cfDNA) in the pregnant woman’s blood is analyzed, usually by next-generation sequencing (NGS), to detect 
potential fetal chromosomal aneuploidies. This approach is possible since a sizable fraction (3–22%) of cfDNA 
in the maternal blood has a fetal origin1,2. Several applications detect chromosomal aneuploidies with high sen-
sitivity and specificity by calculating the relative coverage of all chromosomes in sequenced reads and comparing 
these numbers against a set of reference samples using standard statistical operations3,4. Most of these include 
a mapping stage – reads aligning to the reference genome, which is computationally demanding and requires 
expertise to produce uniform results across samples and populations. Therefore, innovative data analytical solu-
tions are needed to simplify and improve NGS data analysis, like in NIPT, to make it more accessible in clinical 
environment.
Here, we introduce a k-mer-based (k-mer is a short nucleotide sequence with fixed length k) NIPT analysis 
method, referred to as the NIPTmer, a novel software package and workflow process in which the mapping of 
reads is replaced with counting a predefined set of k-mers straight from the FASTQ formatted sequencing raw 
data. Using this approach, NGS data can be analyzed on high-end desktop workstation or a low-end server, 1 to 2 
orders of magnitude faster compared to mapping-based methods.
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Results
Chromosome-specific k-mer lists. Our methodology and its implementation relies on counting pre-de-
fined per-chromosome sets of unique k-mers from the raw sequencing data, applying a linear regression model 
to the chromosome-specific k-mer counts of each studied sample and comparing the predicted and observed 
k-mer counts.
The k-mer length of 25 bases was chosen for this study (see Discussion). By filtering, we excluded (i) k-mers 
that have multiple copies in genome, (ii) k-mers that overlap with common polymorphisms and (iii) k-mers 
that overlap with low-complexity regions (such as telomeres and centromeres) and pseudoautosomal regions of 
chromosomes X and Y. In addition, we removed those k-mers that were specific in human reference genome, but 
for unknown technical or biological reasons were over- or underrepresented in the sequenced healthy euploid 
individuals (see Methods).
The final k-mer list sizes varied between 54,629,103 (chromosome 2) and 5,071,089 (chromosome Y). This 
constitutes about 21.5% (16.7–25.4%) of all possible k-mers in autosomes (Fig. 1). The usable k-mers in chromo-
somes X and Y represented a considerably smaller fraction of all possible k-mers.
K-mer list creation and filtering is the most resource consuming process. However, it has to be done only once 
per platform and per population, and once created, the same lists are used for all subsequent analyses. K-mer lists 
generated for testing our application are available from the NIPTmer download site.
Counting k-mers from reference samples and constructing data-matrix. We constructed 25-mer 
lists from all sequenced reference samples and intersected it with chromosome-specific k-mer lists, obtaining the 
number of chromosome-specific k-mers present in a particular sample. The ratio of the chromosome-specific 
k-mers detected in the sample to the total number of k-mers in corresponding chromosome-specific k-mer list 
gives the relative sequencing coverage of a given chromosome.
The resulting data was a 25 × 583 matrix, where the rows represented different samples and the columns – 22 
autosomes, chromosomes X and Y, and overall GC content in the sample.
Aneuploidy detection. Due to unknown biological and technical variance, the detected per-chromosome 
coverage differs from the expected value when only the total sequencing depth is taken into account. This vari-
ance is partially predictable by a linear regression model that uses the detected coverage of other chromosomes 
as independent variables. Although, the individual coverage values of chromosomes vary between samples, they 
have a certain global pattern that can be used to predict the expected coverages with higher precision. The differ-
ence between the observed and predicted coverage is further normalized by the variance in reference samples. 
The standardized relative difference (z-score) between predicted and observed values is expected to be normally 
distributed, so by setting the cut-off at 3.5 standard deviations, we should get a false positive rate at <0.05%.
NIPTmer testing and validation. To estimate the accuracy of our method and the NIPTmer software 
package, 294 cfDNA samples collected at Tartu University Hospital (Tartu, Estonia) were used. The cohort 
included five samples from pregnancies with trisomy 21 (T21), four samples with trisomy 18 (T18), and one 
mosaic T18 sample. The minimum sequencing coverage of samples was 0.08, average 0.32 and maximum 0.42.
The NIPTmer algorithm discriminated between normal and trisomy cases for all T21 and all non-mosaic 
T18 pregnancies with the z-score being more than 5 standard deviations (SD) greater than normal samples 
(Fig. 2). There was only a slight difference between z-scores of the mosaic T18 and the highest normal sample. 
The data-matrix and z-score matrix derived from our sample set are available in the supplementary materials 
(Supplementary files 1 and 3). The sex of the fetus was determined correctly for all samples.
Figure 1. The number of 25-mers in the final k-mer lists used in the NIPT analysis (black) and the maximum 
number of possible k-mers (white) for each chromosome. The final k-mer lists for autosomes ranged from 
7,781,826 (chr 21) to 54,629,103 (chr 2) unique 25-mers. The lists for chromosomes X and Y were the smallest: 
5,860,559 and 5,071,089 unique 25-mers, respectively.
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In addition, NIPTmer was blindly validated on sequencing data of 289 cfDNA samples of a validation cohort 
from Belgium, which had been described elsewhere3. All non-mosaic aneuploidies, including T21 (15/15), T18 
(10/10), and trisomy 13 (3/3), had higher z-scores than the highest control score, although the difference between 
lowest trisomy and highest normal score was small for trisomies 18 and 21. A single mosaic T13 remained unde-
tected (Fig. 3). The data-matrix and z-score matrix derived from the validation set are available in the supplemen-
tary materials (Supplementary files 2 and 4). The lower discriminative power of our model on validation cohort 
can be explained by larger stochastic variance in validation cohort, caused by lower sequencing coverage. In 
Estonian cohort the average coverage was 0.32, in Belgian cohort 0.13.
NIPTmer computational performance. Software performance tests were conducted on a 32-core 
CentOS 5.10 Linux server (2.27 GHz and 512 gibabytes of RAM). The first step (list preparation) is the most 
time-consuming and, depending on the number of control individuals, takes one to several days. The second step, 
creation of the k-mer list from the sequencing samples and counting unique k-mers takes 4 to 5 minutes with 
180% CPU load. On a laptop with Intel Core i7 processor and 8 GB of RAM, the creation of lists and counting 
unique k-mers took 20 to 25 minutes while using an external drive, and about 10 minutes when data was on the 
internal SSD. The third step, model building and z-score calculation took less than 1 second for 294 samples on 
either platform.
Discussion
NIPTmer is an innovative tool for the rapid and accurate detection of fetal aneuploidies from NGS reads. It works 
by directly counting validated k-mers from sequencing reads and avoids time- and resource-consuming mapping 
of sequencing reads to reference genome, which is a part of most NGS data analysis pipelines5–8.
One of the most crucial and time-consuming parts of the majority of NIPT pipelines is calculating the rela-
tive chromosome coverages from raw sequencing data. The most commonly used method is to map the reads to 
the reference genome and to estimate the coverage by counting the number of reads mapped to each chromo-
some5–8. Due to known issues in mapping certain genomic regions, this step also involves removing reads that 
were mapped to known areas that tend to skew the sequencing results. In NIPTmer, we first construct k-mer 
lists by identifying the sequences (i.e. 25-mers) that represent a particular chromosome the most consistently in 
reference data, and then count only these k-mers directly from the raw sequencing reads. This results in saving of 
both time, as mapping is computationally demanding, and storage space, as there is no need to keep intermediary 
full mapping files, of which only small part is used. The mentioned advantages allow, for example, the constant 
updating of the reference group making the analysis more precise, which is critical in terms of clinical application. 
In addition, reads mapping and relative chromosome coverages calculation operations require higher expertise 
compared to the straightforward k-mers counting, and thus the use of NIPTmer in clinical environment would 
probably be more convenient.
Figure 2. NIPTmer results for 294 subjects of Estonian cohort collected from Tartu University Hospital. 
Chromosome 21 (A) and chromosome 18 (B). Samples are ordered on the x-axis by the order of subject 
enrollment. The y-axis represents the standardized deviation (z-score) between the predicted and observed 
coverage of a given chromosome. Euploid samples are represented by gray points and aneuploid samples by red 
points. If we apply the cut-off line at 3.5 SD, all five T21, four T18 samples and one mosaic T18 case (z-score = 
3.8) are recognized.
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The discriminative power of the NIPTmer method depends both on the quality of DNA preparation and 
sequencing, and per-chromosome k-mer lists. Good k-mer lists should represent each chromosome uniformly 
and uniquely. We used the k-mer length of 25 bases, which is a compromise between specificity and sensitivity9. 
Shorter k-mers are less specific and would thus result in shorter k-mer lists and higher stochastic variance of 
total k-mer counts, making the detection of true variance more difficult. Longer k-mers, although more specific, 
have slightly higher probability of remaining undetected due to sequencing errors or novel mutations that are 
difficult to consider when the k-mer lists are prepared. We analyzed the distribution of final unique 25-mers 
across each chromosome and did not find any clear bias, except the expected lack of unique k-mers at the long 
low-complexity regions like centromeres and telomeres (data not shown). Therefore, in our opinion, increasing k 
would not have contributed to representing the chromosomes more evenly.
We applied multi-step filtering to preliminary k-mer lists, to obtain a set of k-mers that have low variability of 
coverage in most samples and are, thus, suitable for the estimation of relative amount of DNA. It is also possible 
that k-mer lists can be further improved by optimizing the whole selection procedure to minimize the variability 
of total k-mer counts in normal individuals by choosing the optimal combination of included polymorphisms, 
the number of population controls and cut-off values. As this would require substantially larger control dataset, 
preferably including individuals from different populations, it remains for future work.
Figure 3. NIPTmer results for 289 subjects of Belgian cohort. Chromosome 21 (A), chromosome 18 (B) and 
chromosome 13 (C). Samples are ordered on the x-axis by the order of subject enrollment. The y-axis represents 
the standardized deviation (z-score) between the predicted and observed coverage of given chromosome. 
Euploid samples are represented by gray points and aneuploidy samples by red points. All non-mosaic 
aneuploidies, including T21 (15/15), T18 (10/10), and T13 (3/3), had higher z-scores than the highest control 
score, although the difference between lowest trisomy and highest normal score was small for trisomies 18 and 
21. Unfortunately, we could not detect one mosaic T13 with our pipeline.
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In NIPTmer, samples are further analysed by standardizing (z-scoring) the difference of the per-chromosome 
coverage and the predicted coverage for the same chromosome. The z-score is used as an indicator of aneuploidy 
risk for a certain chromosome. However, even most conservative k-mer lists do not guarantee a uniform coverage 
across euploid chromosomes over all samples. The relative coverage (compared to the mean of the whole genome) 
of different chromosomes varies both between chromosomes and between samples. We found that there was a 
certain pattern in the relative coverages of chromosomes, i.e. certain groups of chromosomes showed a tendency 
to have either smaller or higher coverages in a sample. We also found that the average GC content of sequenced 
reads had strong correlation with the relative coverage of different chromosomes. In addition, the average length 
of library fragments correlated with per-chromosome coverages, but due to unreliable measurements, we could 
not use this observation in our calculations. As the relative coverage of different chromosomes had certain pat-
tern, we assumed that it could be estimated by a linear model. The model predicts expected coverage of the chro-
mosome of interest by using the coverages of all other chromosomes and GC content as independent variables. 
The procedure also allows including additional variables that may describe additional relevant parameters of the 
sample. The more detailed description of the relation between the coverages of different chromosomes and sam-
ple GC and the models is given in Supplementary files 6.
As in most available NIPT pipelines, the main qualifier for calling a trisomy in NIPTmer is the z-score of 
observed coverage of the chromosome of interest5–8. Thus, the quality of discrimination depends on the variance 
of respective coverages in control dataset. Although the linear model lowers the variance, the result remains 
stochastic with certain amount of uncertainty. The lower is the sequencing coverage, the higher is stochastic var-
iability and the less powerful is the method. More detailed analysis of the variance at different coverage intervals 
is given in Supplementary files 7. The relative coverage (or z-score) distribution among euploid and aneuploid 
cases probably depends on both technological (cfDNA extraction method, sequencing library preparation, NGS 
technology, and equipment used) and biological (gestational age, overall health of mothers, population) factors. 
Thus, the actual cut-offs for calling the elevated risk of common autosomal trisomies should be defined in every 
NIPT laboratory separately. These cut-offs determine the predictive power and the proportions of false-negative 
and false-positive NIPT results. Setting cut-off value too stringently would minimize the number of false-positive 
results and eventually enables to reduce significantly the number of invasive prenatal tests, which is one of the 
issues addressed by NIPT. However, it should be kept in mind that this will introduce a number of false-negatives 
that must be avoided. Therefore, defining cut-off values for calling the elevated risk of fetal aneuploidy is crit-
ical. The importance of choosing suitable cut-offs in every separate NIPT laboratory can be illustrated by our 
study, where different cut-off values should be applied for Estonian and Belgian cohorts. Overall, in our case, the 
relatively low discriminating power in Belgian cohort associated with lower z-scores of trisomy samples when 
compared to Estonian trisomy samples and thus the need to adjust cut-off values, could be explained by several 
factors, including approximately two-fold lower coverage (0.32 vs 0.13) and shorter reads length (85 bp vs 50 bp) 
compared to Estonian cohort. In addition, it cannot be excluded that the reference group of Estonian origin used 
for analysis of both, Estonian and Belgian, cohorts, did not suit the best in the latter case and could influence the 
results obtained for the Belgian cohort.
NIPTmer also gives the estimation of sequencing uniformity in the form of Mahalanobis distance of a given 
sample. High values of this parameter indicate that sample is not typical, either because it has chromosomal ane-
uploidy or there was some other cause of variance between the relative sequencing coverage of different chromo-
somes. We did not use this value in our validation due to too small sample sizes, but in the future, it can be used 
to indicate the need of re-sequencing or further study.
Another thing that was not considered in the current study is fetal fraction (FF) or the proportion of fetal 
cfDNA to the total cfDNA of a sample. Because cfDNA is a mixture of both maternal and fetal cfDNA, the abil-
ity to detect fetal chromosomal aneuploidies is directly related to FF. Too low FF (<4%, a common minimum 
threshold) may give rise to a false negative result, as the difference in the ratio of an aberrant chromosome would 
be insufficient to distinguish10. Therefore, it is important to estimate FF accurately, although currently there is 
a lack of standardisation in this field11. Several approaches for FF calculation have been proposed that differ by 
the target domain of the fetal-derived sequence being measured by the assay, specificity, reproducibility and the 
cost11,12. However, no large-scale comparison between different measurement methods has been done, therefore 
none of them can be considered a “standard” FF measurement11. Current NIPTmer version does not calculate FF, 
although this step should be incorporated into the analysis pipeline in the future. One possibility is to use SeqFF 
approach that is based on the principle of size fractionation and does not require any additional experiments 
while calculating FF from shallow-depth single-end sequencing data13.
Although the discriminative power of NIPT can probably be further increased, it cannot completely replace 
ultrasound screening and cytogenetic analyses in the near future. The known weak spot of NIPT is associated 
with possible fetal mosaicism. As the fetal cfDNA, in fact, originates from the placenta, NIPT will miss the cases 
where placenta is euploid while fetus is fully or partially aneuploid, resulting in false negatives. For example, a 
mosaic T13 sample from the validation dataset was not detected with our pipeline. Also, the mosaic T18 in our 
test data had significantly lower z-score compared to full trisomy cases. Although setting the cut-off at 3.5 SD 
would enable to discriminate this specific mosaic T18 case in our dataset, we expect that this would also increase 
a number of false positive results in future tests. After all, NIPT is a method for evaluating the genotype, but the 
ultimate goal of prenatal testing is to determine the phenotype of fetus.
In summary, NIPTmer is an innovative tool for the ultra-rapid analysis of NIPT data. NIPTmer replaces 
time-consuming sequencing read mapping with a resource-saving k-mer counting strategy. In addition to its 
high performance, NIPTmer provides accurate and robust detection of common autosomal fetal trisomies, as was 
demonstrated in two independent cohorts.
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Methods
Samples. NIPTmer was tested using two sets of cfDNA samples of pregnant women, one from Estonia 
and another from Belgium. The Estonian sample set consisted of 294 samples and was used to train NIPTmer 
algorithm. Sequencing libraries were generated using Illumina TruSeq ChIP Sample Preparation kit (Illumina 
Inc., San Diego, CA, USA) and sequenced on Illumina NextSeq 500 instrument with an average coverage of 
0.32 × (minimum 0.08, maximum 0.42) producing 85 bp single-end reads. The Belgian dataset, published previ-
ously3, consisted of 289 samples and was used in a blind test to validate the algorithm by comparing the results of 
the two pipelines. Libraries were prepared using TruSeq ChIP Sample Preparation kit (Illumina) and sequenced 
on Illumina HiSeq 2500 producing 50 bp single-end reads with an average coverage of 0.13x3.
The study was approved by Research Ethics Committee of the University of Tartu (#246/T-21) and written 
informed consent was obtained from all participants. All experiments were performed in accordance with rele-
vant European guidelines and regulations.
NIPTmer pipeline. NIPTmer pipeline consists of three main steps: (1) creating k-mer lists, (2) counting the 
k-mers from the samples, and (3) calling the aneuploidy based on the counts.
Step 1: Creation of k-mer lists. Creating k-mer lists from FASTQ files and conducting intersection and 
subtraction operations with the k-mer lists was done using GenomeTester4 toolkit14. Figure 4 gives the overview 
of the creation of k-mer lists.
The first step is a multistage process in which a list of unique reference k-mers is generated for each chromo-
some. The initial list containing all possible k-mers in a given chromosome was refined by excluding (subtracting) 
certain groups of k-mers and intersecting it with a list of stable k-mers. In the first stage, the list of non-unique 
k-mers was subtracted from the initial chromosome-specific k-mer lists to ensure that only unique k-mers are 
included in the final step. In the second stage, k-mers that overlap with any allele of known polymorphisms were 
removed to ensure that the list is universal for all individuals and ethnic groups. Specifically, a FASTA file was 
generated containing regions with possible allele combinations of known polymorphisms in dbSNP with MAF 
above 1%. All k-mers in obtained file were removed from chromosome-specific k-mer lists. In our analysis, the 
human reference genome version GRCh37 and dbSNP polymorphism database version 147 was used.
Low-complexity repeats are known to cause variability in sequencing data and, therefore, should be excluded 
from the final k-mer lists. In the third stage, known low-complexity repeats, including telomeric and centromeric 
regions, and pseudoautosomal regions were removed by constructing FASTA files containing known problematic 
regions and subtracting all k-mers of obtained file from chromosome-specific k-mer lists. The low complexity 
regions were downloaded from 1000 Genomes project.
Finally, full-genome sequencing data of euploid control individuals were used to obtain a list of k-mers that 
have the expected frequency distribution in the control population. This list enables to account for sequencing 
bias, contamination, copy number variations, and other unaccounted sources of k-mer variation. Sequencing of 
control and NIPT samples should be performed on the same or similar platforms, but the coverage for control 
samples must be significantly higher.
The numbers of reads from each genomic location in control samples, and thus the observed number of copies 
of each unique k-mer, were approximated with a Poisson distribution with the mean being the average sequencing 
depth. First, a raw k-mer list was constructed from the sequencing reads of each control individual. High and 
low cut-off values of k-mer counts were calculated based on the cumulative Poisson distribution, with the actual 
sequencing coverage as a mean. The probability of the observed k-mer count may be too low, and the k-mer 
Figure 4. Creation of per-chromosome k-mer lists is composed of the following steps: creating lists of per-
chromosome k-mers from reference genome; removing non-unique k-mers; removing potentially polymorphic 
k-mers; removing k-mers from problematic regions of genome like centromeres, telomeres, pseudoautosomal 
regions etc; and intersecting with list of k-mers that have normal copy number in population.
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unsuitable for further workflow, if (i) the given k-mer is not present in exactly two copies in a given genome or (ii) 
the given part of genome has strong sequencing bias. For each control individual, a list of k-mers was constructed 
with a count between the calculated cut-off values. In the current study, 50 control samples from EGCUT15 were 
used with the probability cut-offs 0.01 and 0.99. Sequencing of control individuals was performed on Illumina 
HiSeq 2500 system with coverage of 20–30x. The intersection of all per-individual lists gave a per-population list 
of stable k-mers. By intersecting this list with per-chromosome k-mer lists, final filtered per-chromosome lists 
were obtained.
Detailed description of each step can be found in supplementary materials (Supplementary files 5, section A).
Step 2: Counting sample-specific k-mers. First, the sequencing reads in raw FASTQ files of a sample 
were converted to 25-mer list. The obtained k-mer list was intersected one-by-one with all chromosome-specific 
filtered k-mer lists and thus, the number of k-mers specific to each chromosome in a particular sample (Ksc) 
was found. In addition, the average GC content of sequenced reads (GCS) was calculated. All operations in this 
step were performed using GenomeTester4 toolkit14. The details are available in the supplementary materials 
(Supplementary files 5, section B).
Step 3: Coverage model for aneuploidy calling. The input for risk score calculation section was a 
data-matrix containing raw count of unique k-mers for each sample and each chromosome, as well as the number 
on k-mers in the reference k-mer lists and GC content of the sequences.
Aneuploidy of a certain chromosome was called based on the increase or decrease of its coverage compared 
to expected value for this sample. These changes are usually small, because the major part of cfDNA originates 
from mother’s euploid cells. If n% of the total cfDNA is of fetal origin, then, in case of full non-mosaic trisomy, the 
relative change of coverage of one chromosome is (Equation 1):
100 3
2
n (100 n) 1
(1)


 +


 ÷ + −
Thus, a good prediction of expected coverage is crucial in order to detect minor changes in coverage.
Per-sample per-chromosome coverage (Csc) was calculated by dividing the k-mer count by the k-mer list 
length (Lc) of a given chromosome (Equation 2):
=C K
L (2)SC
SC
C
Csc – per-sample per-chromosome coverage
Ksc – number of chromosome-specific k-mers in a sample
LC – total number of chromosome-specific k-mers in k-mer list
According to our analysis, the relative coverages Csc of different chromosomes varied even in euploid samples. 
The effect, which is mostly consistent between samples, depended on the GC content of a chromosome, GC con-
tent of a sample and possibly on other factors as well. Because of this variance between the samples, the average 
sequencing coverage could not be reliably used and more precise linear model was constructed16 (Equation 3):
ˆ (X X) X y (3)T 1 Tβ = −
β – regression coefficient vector
X – coverage matrix Csc excluding the parameter at hand (chromosome or GC)
y – vector of values of given parameter
The regression coefficients calculated in the previous step were used to predict expected per-chromosome 
coverages of a new sample (Equation 4):
′ =β +β + ... +β +βC C C C GC (4)SC 1 1 2 2 22 22 GC
C′SC – predicted per-sample per-chromosome coverage
β1… β22, βGC – model coefficients
GC – the average GC content of a sample
Separate linear regression models were built for each chromosome so that Csc of a given chromosome was the 
dependent variable and all other chromosomal coverages and the GC content of the sample were independent 
variables. Expected coverages (C′sc) of chromosomes were calculated based on those models for each sample in 
analysis.
To determine the sex of a fetus, four sex chromosome models (X female, X male, Y female and Y male) were 
created to predict the expected coverages of sex chromosomes based on autosome coverage. Model parameters 
were estimated using a reference dataset of 150 euploid pregnancies. The model for autosomes was calculated 
using all reference samples. For sex chromosome models, only samples from pregnancies with fetus of the corre-
sponding sex were used.
By applying these models on an unknown sample, the expected coverages of all chromosomes were obtained, 
assuming that the sample was similar to the reference (i.e. euploid). For sex chromosomes, four expectation 
values were obtained – two based on the assumption that the fetus was a male and two on the assumption that it 
was a female.
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The difference between predicted and actual per-chromosome coverage was expected to have normal distribu-
tion, given uniform sequencing depth. To make the algorithm less dependent on sequencing depth, a difference 
can be normalized by dividing the actual difference with the observed per-chromosome coverage (Equation 5):
D C C
C (5)SC
SC SC
SC
=
− ′
′
Dsc – normalized difference between observation and prediction
Csc – per-sample per-chromosome coverage
C′SC – predicted per-sample per-chromosome coverage
Samples were analysed by standardizing (z-scoring) the difference of the per-chromosome coverage and the 
predicted coverage (Dsc) for the same chromosome. For standardization, the data of reference group was used to 
find the mean difference and the standard deviation (Equation 6):
Z
D average(D )
SD(D ) (6)
SC
SC SC,ref
SC,ref
=
−
ZSC – Z-score of model prediction for specific sample and chromosome
Dsc – difference between observation and prediction
Dsc,ref – difference between observation and prediction of reference population
The z-score was used as the indicator of aneuploidy risk for a certain chromosome. The practical z-score 
cut-off values, indicating the elevated risk for fetal aneuploidies, depend on the reference and test populations, 
sequencing technology, and coverage used. Therefore, these values must be determined experimentally.
The Mahalanobis distance of a given sample from the reference set can be used to estimate DNA preparation 
and sequencing quality (Equation 7):
    
= − −−D C C C S C C( ) ( ) ( ) (7)M S S
T
S
T1
DM – Mahalanobis distance
CS

– vector of all normalized per-chromosome coverages plus GC of analyzed sample
C

– vector of averages of per-chromosome coverages plus GC in control dataset
S−1 – covariance matrix of CSC plus GC in control dataset
The workflow for aneuploidy calling step is summarized in Fig. 5. The details are available in the supplemen-
tary materials (Supplementary files 5, section C).
Figure 5. Data flow during aneuploidy calling step. Raw counts of each chromosome are divided by the length 
of k-mer list of respective chromosome to obtain the coverage. The coverage is separated between sample 
group and reference group. Only reference group is used to generate the linear regression model and later to 
calculate the average and standard deviation between the observed and predicted coverages. Z-score is used 
to call the aneuploidy. Cut-off is customizable depending on the type 1 and type 2 error tolerated in the study. 
Mahalanobis distance is used as a quality control parameter.
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